Roivant Sciences Ltd. — Form 10-Q Summary
Business context and reporting period
This filing covers the fiscal third quarter ended December 31, 2021, and the nine months then ended, with comparisons to the corresponding 2020 periods. Although the request metadata says “2020 Q3,” the filing itself is for 2021 Q3 (fiscal year ending March 31). The financial statements are unaudited. Roivant develops medicines through its Vant subsidiaries and reported a pipeline of more than 30 drug candidates. It had not generated revenue from product sales.
Key financial metrics
Amounts below are in millions of U.S. dollars, except per-share data.
| Metric | Three months ended Dec. 31, 2021 | Three months ended Dec. 31, 2020 | Nine months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2020 |
|---|---|---|---|---|
| Revenue | $24.3 | $5.8 | $46.1 | $8.6 |
| Operating expenses | $270.4 | $264.8 | $1,130.9 | $538.7 |
| Operating loss | $(246.0) | $(259.1) | $(1,084.8) | $(530.1) |
| Net loss | $(306.1) | $(275.6) | $(632.8) | $(337.1) |
| Net loss attributable to Roivant | $(284.5) | $(261.0) | $(575.2) | $(299.7) |
| Basic and diluted loss per share | $(0.41) | $(0.41) | $(0.87) | $(0.48) |
- Cash and liquidity: Cash and cash equivalents were $2,214.3 million at December 31, 2021; total cash, cash equivalents and restricted cash were $2,226.1 million. Current assets were $2,287.5 million and current liabilities $160.7 million.
- Cash flow: For the nine months, operating activities used $530.3 million, investing activities provided $309.0 million and financing activities provided $305.7 million. Operating cash use was $446.1 million in the 2020 comparison period.
- Debt: Long-term debt, net, was $204.0 million, against principal of $211.9 million. The debt includes Dermavant borrowings; a $40 million Dermavant facility carries 10% annual interest and a five-year maturity.
- Margins: The filing reports substantial operating losses and no meaningful product-sales base; it does not present a standalone operating-margin measure.
Material changes and unusual items
- Nine-month operating expenses more than doubled year over year. R&D rose to $486.3 million from $358.4 million, while general and administrative expense rose to $636.1 million from $178.7 million. Quarterly R&D declined year over year, largely because the prior-year quarter included greater in-process R&D acquisition and licensing costs.
- Share-based compensation was $487.8 million for the nine months, including a $372.9 million one-time catch-up expense associated with liquidity-event vesting upon the September 2021 business combination. This noncash item significantly affected reported expenses and net loss.
- The Datavant merger generated approximately $320 million of cash proceeds and a $443.8 million accounting gain on remeasurement of the retained investment. Roivant also reported a $66.5 million gain related to termination of Sumitomo options.
- The September 2021 business combination and PIPE financing brought in $213.4 million net cash at closing. In November, Roivant settled $100 million of Silicon Therapeutics consideration with $50 million cash and 6.35 million shares.
- Investment fair-value movements were material and volatile. Datavant’s retained interest was a Level 3 fair-value investment valued at $215.7 million at December 31, 2021; public-company holdings included Arbutus and Sio.
Outlook, commentary and risks
- Management stated that existing cash and cash equivalents were expected to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the statements. It also expects continuing losses and increasing expenses, and says additional capital may be needed; financing may dilute shareholders or require changes to development plans.
- Near-term company-stated catalysts included an FDA decision on tapinarof for psoriasis expected in Q2 2022; Immunovant’s planned Phase 3 myasthenia gravis trial initiation in the first half of 2022; and other clinical program starts and data readouts. Timings were expectations, not guarantees.
- Roivant reported that COVID-19 had disrupted some trial sites and delayed certain development timelines, but had not caused material financial impacts through the reporting period. Future effects remained uncertain.
- Immunovant’s batoclimab trials had been paused in February 2021 after elevated cholesterol and LDL observations; the subsidiary later reported FDA alignment to proceed in myasthenia gravis. Safety, trial execution, regulatory approval, manufacturing, intellectual-property protection and access to financing remain significant risks.
- A securities class action involving Immunovant was amended on February 1, 2022 to add Roivant and other defendants. Roivant said it intends to defend the case and had not recorded a liability because losses could not then be reasonably estimated. No material probable and estimable legal loss was reported.
- Management concluded disclosure controls were effective as of December 31, 2021 and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether tapinarof’s regulatory decision and other pipeline milestones occurred on the stated timelines, and the clinical and regulatory evidence supporting them.
- Cash burn, committed spending and runway against management’s 12-month estimate, including the need and terms of any future financing.
- The recurring versus one-time components of share-based compensation and other unusual gains or fair-value changes when assessing underlying operating performance.
- The valuation assumptions and potential variability of the Datavant Level 3 investment, and the value and liquidity of other subsidiary interests.
- Developments in the amended securities litigation, batoclimab safety and clinical progress, and any resulting financial or operational effects.